Exhibit 99.1



Align Technology Ethos Communication
Madelyn Homick Shannon Mangum Henderson
(408) 470-1180  (678) 261-7803
mhomick@aligntech.com align@ethoscommunication.com





Q2 revenues up 37.5% year-over-year to a record $490.3 million, and diluted EPS of $1.30
Q2 operating income up 46.8% year-over-year to $122.7 million, operating margin of 25.0%
Q2 total Invisalign case shipments up 30.5% year-over-year to 302.7 thousand
Q2 Invisalign cases for teenage patients up 42.1% year-over-year to 78.4 thousand
Q2 iTero scanner and services revenues up 60.9% year-over-year to $57.0 million


SAN JOSE, Calif., July 25, 2018 -- Align Technology, Inc. (Nasdaq: ALGN) today reported financial results for the second quarter ended June 30, 2018. Invisalign case shipments in the second quarter of 2018 (Q2’18) were 302.7 thousand, up 30.5% year-over-year. Americas and International region case shipments were up year-over-year 22.2% and 45.4%, respectively. Q2’18 Invisalign cases for teenage patients were 78.4 thousand, up 42.1% year-over-year. Q2’18 revenues were $490.3 million, up 37.5% year-over-year and Q2’18 operating income was $122.7 million, up 46.8% year-over-year resulting in an operating margin of 25.0%. Net profit was $106.1 million, or $1.30 per diluted share, up $0.45 year-over-year.


Commenting on Align’s Q2 2018 results, Align Technology President and CEO Joe Hogan said, “I’m pleased to report another better than expected quarter for Align. Our second quarter results reflect strong growth across our customer channels with record volume in all regions and in almost every country market. Year-over-year revenue growth of 37.5% was driven by continued momentum from Invisalign doctors and increased adoption of Invisalign treatment for teenage patients which grew 42.1%. Q2 Invisalign volume growth of 30.5% year-over-year reflects increased utilization and expansion of our customer base, which was over 50,000 for the first time and included more than 5,000 new Invisalign-trained doctors. We also saw momentum from the iTero scanner and services business which includes the continued rollout of iTero scanners across Heartland Dental’s installed base, as well as the first iTero scanner shipments to China.”


GAAP Summary Financial Comparisons

Second Quarter Fiscal 2018

  Q2’18 Q1’18 Q2’17  Q/Q Change  Y/Y Change
Invisalign Case Shipments1 302,685 272,235 231,890 +11.2% +30.5%
Net Revenues $490.3M $436.9M $356.5M +12.2% +37.5%
    Clear Aligner2 $433.3M $385.5M $321.0M +12.4% +35.0%
    Scanner & Services $57.0M $51.4M $35.4M +10.9% +60.9%
Net Profit $106.1M $95.9M $69.2M +10.7% +53.4%
Diluted EPS $1.30 $1.17 $0.85 +$0.13 +$0.45


  - 1 - 


Note: Changes and percentages are based on actual values and may affect totals due to rounding

1 Invisalign shipment figures do not include SmileDirectClub aligners

2 Clear aligner revenue includes revenues from Invisalign clear aligners and SmileDirectClub aligners


As of June 30, 2018, Align had $720.7 million in cash, cash equivalents and marketable securities compared to $673.0 million as of March 31, 2018. In May 2018, we announced an additional $600 million stock buy-back authorization. We also have $100 million remaining under the April 2016 repurchase program, which we expect to utilize during the remainder of 2018.


Announcements and Highlights

·Today, Align issued a separate press releases announcing that the Company has opened new facilities in Costa Rica to support continued long term growth. The Company hosted a grand opening celebration on Friday, July 20 attended by Costa Rican President Carlos Alvarado Quesada and local government officials. Today, the Company also announced that it has received Certificate of Medical Device Registration and Certificate of Production from the China Food and Drug Administration (CFDA) to manufacture the iTero Element intraoral scanner in China. Align had previously announced in April that it had received approval from the CFDA to market the iTero Element intraoral scanner in China.


Q2 2018 Company Highlights. During the second quarter Align announced the following:


·The One Millionth Invisalign case for the Europe, Middle East and Africa (“EMEA”) region.  This is a significant milestone for the Company with more than 34 thousand Invisalign-trained orthodontists and general dentists in the region and reflects accelerating adoption of Invisalign clear aligner therapy in EMEA.
·Eleven recipients of research grants under the Company’s Annual Research Award Program. Now in its ninth year of funding, nearly $300,000 has been awarded for 2018 to researchers at universities in the Americas, Europe, and Asia Pacific regions.
·The grand opening of the first Invisalign treatment planning facility in Europe, located in Cologne, Germany. The Cologne facility is one of only three Invisalign treatment planning facilities in the world and reflects the rapid growth and expansion of Align globally. It serves as a training facility for Invisalign doctors within the German-speaking market, providing clinical education and support in local language for doctors in Germany, Austria, Switzerland and Lichtenstein.
·The extension of the Invisalign product family with Invisalign First clear aligners, designed with features specifically for younger patients with early mixed dentition (mixture of primary/baby and permanent teeth). Phase 1 treatment is early interceptive orthodontic treatment for young patients, traditionally done through arch expanders, or partial metal braces, before all permanent teeth have erupted - typically at ages 6 through 10 years. Invisalign First clear aligners are designed specifically to address a broad range of younger patients' malocclusions, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion.
  - 2 - 


·A new expanded Invisalign product portfolio that includes new options and greater flexibility to treat a broader range of patients. The new Invisalign product portfolio offers doctors more choices by extending desirable features across the entire portfolio and creating new Invisalign Treatment Packages, as well as new options to treat young patients with early mixed dentition. The new end-to-end Invisalign portfolio now includes clear aligner product offerings for almost every patient age group and case complexity to make it easier for doctors to tailor treatment planning to the needs of each unique patient.
·The new Invisalign Go product with a more user-friendly iTero digital chairside experience and greater flexibility to treat a wider range of mild to moderate cases such as crowded or gap teeth that require teeth straightening prior to restorative treatments. Invisalign Go also incorporates new data-driven clinical protocols for predictable tooth movement and automated case assessments that leverage over 5.5 million Invisalign patients treated to date. These improvements make it easier for dentists to tailor their treatment plans to the individual needs of each patient.
·The commercial availability of Vivera Retainers with Precision Bite Ramps, the first retainers in the market that can be customized to provide additional support after deep bite correction. First introduced in 2014 with Invisalign G5 Innovations, Precision Bite Ramps are designed to disocclude the posterior teeth or "open the bite" for improved efficiency in deep bite Invisalign treatments.
·The expansion of the iTero Element portfolio with the launch of the iTero Element 2 and the iTero Element Flex scanners. These additions build on the existing high precision, full-color imaging and fast scan times of the iTero Element portfolio. The next-generation iTero Element 2 is designed for greater performance with 2X faster start-up and 25% faster scan processing time compared to the iTero Element.
·Regulatory approval from the China Food and Drug Administration (CFDA) to market the iTero Element intraoral scanner in China.


Q3 2018 Business Outlook

For the third quarter of 2018 (Q3’18), Align provides the following guidance:


·Net revenues in the range of $493 million to $503 million, up approximately 28% to 31% over the same period a year ago
·Invisalign case shipments in the range of 302 thousand to 307 thousand, up approximately 28% to 30% over the same period a year ago
·Operating margin in the range of 24.2% to 24.9%
·Diluted EPS in the range of $1.13 to $1.18


  - 3 - 


Align Web Cast and Conference Call

Align will host a conference call today, July 25, 2018 at 4:30 p.m. ET, 1:30 p.m. PT, to review its second quarter 2018 results, discuss future operating trends and the business outlook. The conference call will also be web cast live via the Internet. To access the webcast, go to the “Events & Presentations” section under Company Information on Align’s Investor Relations web site at http://investor.aligntech.com. To access the conference call, please dial 201-689-8261. An archived audio web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with conference number 13681104 followed by #. For international callers, please dial 201-612-7415 and use the same conference number referenced above. The telephonic replay will be available through 5:30 p.m. ET on August 8, 2018.


About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align’s products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.


For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com.


Forward-Looking Statement

This news release, including the tables below, contains forward-looking statements, including statements regarding certain business metrics for the third quarter of 2018, including, but not limited to, anticipated net revenues, gross margin, operating expenses, operating profit, diluted earnings per share, tax rate including the financial impact of recent U.S. Tax Cuts and Jobs Act and case shipments. Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. Factors that might cause such a difference include, but are not limited to, difficulties predicting customer and consumer purchasing behavior, Align's ability to protect its intellectual property rights, continued compliance with regulatory requirements, competition from existing and new competitors, the willingness and ability of our customers to maintain and/or increase product utilization in sufficient numbers, the possibility that the development and release of new products does not proceed in accordance with the anticipated timeline, the possibility that the market for the sale of these new products may not develop as expected, or that the expected benefits of new or existing business relationships will not be achieved as anticipated, risks relating to international sales, which are increasingly a larger portion of our total revenues, the risks relating to Align's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses, growth related risks, including capacity constraints and pressure on our internal systems and personnel, the security of customer and/or patient data is compromised for any reason, continued customer demand for our existing and new products, changes in consumer spending habits as a result of, among other things, prevailing economic conditions, levels of employment, salaries and wages and consumer confidence, the timing of case submissions from our doctors within a quarter, acceptance of our products by consumers and dental professionals, changes to our interpretation of the U.S. Tax Cuts and Jobs Act which may change as we receive additional clarification and implementation guidance, possibly materially, foreign operational, political and other risks relating to Align's international manufacturing operations, litigation risks, uncertainties involved in any contract dispute resolution and the possibility of Align choosing to settle the litigation for business or other reasons. Align's ability to develop and successfully introduce new products and product enhancements and the loss of key personnel. These and other risks are detailed from time to time in Align's periodic reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 28, 2018. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.


  - 4 - 



(in thousands, except per share data)            
   Three Months Ended
June 30,
  Six Months Ended
June 30,
   2018  2017  2018  2017
Net revenues  $490,259   $356,482   $927,183   $666,823 
Cost of net revenues   124,677    85,565    234,193    160,281 
Gross profit   365,582    270,917    692,990    506,542 
Operating expenses:                    
Selling, general and administrative   212,087    162,964    411,712    314,112 
Research and development   30,804    24,384    60,395    47,188 
Total operating expenses   242,891    187,348    472,107    361,300 
Income from operations   122,691    83,569    220,883    145,242 
Interest income   1,917    1,441    4,093    2,636 
Other income (expense), net   (7,099)   1,771    (6,922)   2,221 
Net income before provision for income taxes and equity in losses of investee   117,509    86,781    218,054    150,099 
Provision for income taxes   7,703    15,387    10,605    8,164 
Equity in losses of investee, net of tax   3,701    2,215    5,478    3,336 
Net income  $106,105   $69,179   $201,971   $138,599 
Net income per share:                    
Basic  $1.32   $0.86   $2.52   $1.73 
Diluted  $1.30   $0.85   $2.48   $1.70 
Shares used in computing net income per share:                    
Basic   80,216    80,188    80,127    80,047 
Diluted   81,471    81,631    81,575    81,668 

* During Q1'18, we adopted the ASC 606, "Revenues from Contracts with Customers" using the full retrospective method. The adoption of ASC 606 did not have a material impact on our Condensed Consolidated Statements of Operations presented herein.


  - 5 - 



(in thousands)      
    June 30,
    December 31,
Current assets:          
Cash and cash equivalents  $547,993   $449,511 
Marketable securities, short-term   164,629    272,031 
Accounts receivable, net   374,371    324,189 
Inventories   47,252    31,688 
Prepaid expenses and other current assets   126,754    80,948 
Total current assets   1,260,999    1,158,367 
Marketable securities, long-term   8,061    39,948 
Property, plant and equipment, net   447,933    348,793 
Equity method investments   49,128    54,606 
Goodwill and intangible assets, net   85,307    89,068 
Deferred tax assets   45,859    49,334 
Other assets   19,302    43,893 
Total assets  $1,916,589   $1,784,009 
Current liabilities:          
Accounts payable  $48,744   $36,776 
Accrued liabilities   196,754    195,562 
Deferred revenues   321,148    267,713 
Total current liabilities   566,646    500,051 
Income tax payable   115,701    114,091 
Other long-term liabilities   15,283    15,579 
Total liabilities   697,630    629,721 
Total stockholders' equity   1,218,959    1,154,288 
Total liabilities and stockholders' equity  $1,916,589   $1,784,009 


* During Q1'18, we adopted the ASC 606, "Revenues from Contracts with Customers" using the full retrospective method. Condensed Consolidated Balance Sheet as of December 31,2017 has been recasted to comply with the adoption.


  - 6 - 



(in thousands)      
   Six Months Ended
June 30,
   2018  2017
Net income  $201,971   $138,599 
Net cash provided by operating activities   217,121    158,088 
Net cash provided by (used in) investing activities   54,003    (111,718)
Net cash used in financing activities   (170,745)   (84,240)
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash   (1,923)   3,640 
Net increase (decrease) in cash, cash equivalents, and restricted cash   98,456    (34,230)
Cash, cash equivalents, and restricted cash at beginning of the period   450,125    393,019 
Cash, cash equivalents, and restricted cash at end of the period  $548,581   $358,789 


*During Q1'18, we adopted ASU 2016-18, "Statement of Cash Flows - Restricted Cash" on a retrospective basis. Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2017 has been recasted to comply with the adoption. 


  - 7 - 



   Q1  Q2  Q3  Q4  Fiscal  Q1  Q2
   2017  2017  2017  2017  2017  2018  2018
Invisalign Average Selling Price (ASP):                         
Worldwide ASP   $1,270   $1,285   $1,310   $1,305   $1,295   $1,310   $1,315 
International ASP  $1,345   $1,340   $1,395   $1,400   $1,375   $1,435   $1,425 
Invisalign Cases Shipped by Geography:                                   
Americas   134,450    148,470    147,660    155,625    586,205    166,665    181,425 
International   73,610    83,420    88,405    99,405    344,840    105,570    121,260 
Total Cases Shipped   208,060    231,890    236,065    255,030    931,045    272,235    302,685 
YoY % growth   27.1%   31.0%   32.8%   34.2%   31.4%   30.8%   30.5%
QoQ % growth   9.5%   11.5%   1.8%   8.0%        6.7%   11.2%
Number of Invisalign Doctors Cases Were Shipped To:                                   
Americas   24,595    25,570    25,865    26,480    38,230    27,105    28,280 
International   14,270    15,695    16,740    18,505    26,175    19,700    21,805 
Total Doctors Cases Shipped To   38,865    41,265    42,605    44,985    64,405    46,805    50,085 
Invisalign Doctor Utilization Rates**:                                   
North America   5.6    5.9    5.8    6.0    15.8    6.3    6.6 
North American Orthodontists   12.6    13.6    13.8    14.0    46.6    15.3    16.4 
North American GP Dentists   3.1    3.3    3.1    3.3    8.2    3.4    3.6 
International   5.2    5.3    5.3    5.4    13.2    5.4    5.6 
Total Utilization Rates   5.4    5.6    5.5    5.7    14.5    5.8    6.0 
Number of Invisalign Doctors Trained:                                   
Americas   1,040    1,820    1,740    1,685    6,285    1,605    1,795 
International   2,220    3,055    2,540    2,400    10,215    2,645    3,300 
Total Doctors Trained Worldwide   3,260    4,875    4,280    4,085    16,500    4,250    5,095 
Total to Date Worldwide   118,730    123,605    127,885    131,970    131,970    136,220    141,315 


Note: Historical public data may differ due to rounding. Additionally, rounding may effect totals. Effective Q1'18, Americas region includes North America and LATAM. International region includes EMEA and APAC. We have recasted historical data to reflect the change.

* Invisalign business metrics exclude SmileDirectClub aligners. 

** # of cases shipped / # of doctors to whom cases were shipped. LATAM utilization rate is not separately disclosed, but included in the total utilization rates. 



(in thousands)   
   Q1  Q2  Q3  Q4  Fiscal  Q1  Q2
   2017  2017  2017  2017  2017  2018  2018
Stock-based Compensation (SBC)                                   
SBC included in Gross Profit  $925   $768   $833   $804   $3,330   $881   $900 
SBC included in Operating Expenses   13,887    13,477    14,134    14,026    55,524    14,949    15,990 
Total SBC Expense  $14,812   $14,245   $14,967   $14,830   $58,854   $15,830   $16,890 


  - 8 - 



The outlook figures provided below and elsewhere in this press release are approximate in nature since Align’s business outlook is difficult to predict.  Align’s future performance involves numerous risks and uncertainties and the company’s results could differ materially from the outlook provided.  Some of the factors that could affect Align’s future financial performance and business outlook are set forth under “Forward Looking Information” above in this press release.  


Financial Outlook      
(in millions, except per share amounts and percentages)  
    Q3'18 Guidance  
Net Revenues   $493 - $503  
Gross Margin   74.0% - 74.4%  
Operating Expenses   $245 - $249  
Operating Margin   24.2% - 24.9%  
Net Income per Diluted Share   $1.13 - $1.18 (1, 2)
Business Metrics:   Q3'18  
Case Shipments   302K - 307K  
Capital Expenditure   $60M - $65M  
Depreciation & Amortization   $10M - $11M  
Diluted Shares Outstanding   81.6M (2)
Stock Based Compensation Expense   $18.8M  
Effective Tax Rate   ~21% (1)
(1) Includes excess tax benefits related to share-based compensation expense pursuant to ASU 2016-09
(2) Excludes any stock repurchases during the quarter



- 9 -  

View differences made from one to another to evaluate Align Technology Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Align Technology Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account